NCT07415005 2026-02-17Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung CancerM.D. Anderson Cancer CenterPhase 2 Not yet recruiting30 enrolled
NCT04541706 2024-12-20Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in IndiaPfizerPhase 4 Completed100 enrolled 10 charts